Comments
Natco Pharma Ltd’s consolidated net profit declined 34.5 per cent at ₹104 crore in the third quarter ended December 31, 2019 compared to ₹159 crore in the same period last year.
The total revenue of the company also decreased to ₹513 crore from ₹580 crore in the corresponding quarter of previous financial year. “The company continues to face margin pressure,’’ Natco said in a release issued here on Wednesday.
The board of directors has recommended a third interim dividend of ₹3.50 per equity share of ₹2 each.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.